- Credit Suisse downgraded Immunovant Inc IMVT to Underperform from Neutral and lowered the price target to $7 from $12.
- Analyst Tiago Fauth says that the downgrade reflects ongoing clinical and regulatory uncertainties for IMVT-1401 owing to safety concerns, likely extended clinical timelines with no clear value-driving catalysts in the next 12-months.
- According to the analyst, the $200M equity investment from Roivant Sciences has significantly reduced near-term M&A expectations as well.
- In March, Roivant revealed in an SEC filing to acquire all the shares in Immunovant.
- Price Action: IMVT shares are down 23.5% at $8 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
